Aytu Bioscience Stock Price, News & Analysis (NASDAQ:AYTU)

$2.81 0.41 (17.08 %)
(As of 01/16/2018 08:23 AM ET)
Previous Close$2.40
Today's Range$2.43 - $2.90
52-Week Range$2.05 - $23.10
Volume252,300 shs
Average Volume47,778 shs
Market Capitalization$13.76 million
P/E Ratio-0.10
Dividend YieldN/A
Beta5.13

About Aytu Bioscience (NASDAQ:AYTU)

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.

Receive AYTU News and Ratings via Email

Sign-up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AYTU
CUSIPN/A
Phone720-437-6580

Debt

Debt-to-Equity RatioN/A
Current Ratio2.78%
Quick Ratio2.45%

Price-To-Earnings

Trailing P/E Ratio-0.101370814801293
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.22 million
Price / Sales4.28
Cash FlowN/A
Price / CashN/A
Book Value$4.84 per share
Price / Book0.58

Profitability

Trailing EPS($27.72)
Net Income$-22,500,000.00
Net Margins-481.06%
Return on Equity-229.64%
Return on Assets-91.37%

Miscellaneous

Employees63
Outstanding Shares4,900,000

Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions

What is Aytu Bioscience's stock symbol?

Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."

When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?

Aytu Bioscience shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.

How were Aytu Bioscience's earnings last quarter?

Aytu Bioscience Inc (NASDAQ:AYTU) announced its quarterly earnings results on Thursday, November, 9th. The company reported ($1.76) earnings per share for the quarter, beating analysts' consensus estimates of ($7.60) by $5.84. The firm had revenue of $1.08 million for the quarter. Aytu Bioscience had a negative return on equity of 229.64% and a negative net margin of 481.06%. View Aytu Bioscience's Earnings History.

When will Aytu Bioscience make its next earnings announcement?

Aytu Bioscience is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Aytu Bioscience.

Where is Aytu Bioscience's stock going? Where will Aytu Bioscience's stock price be in 2018?

2 brokers have issued 12-month price targets for Aytu Bioscience's stock. Their forecasts range from $3.00 to $3.00. On average, they expect Aytu Bioscience's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for Aytu Bioscience.

Who are some of Aytu Bioscience's key competitors?

Who are Aytu Bioscience's key executives?

Aytu Bioscience's management team includes the folowing people:

  • Joshua R. Disbrow, Chief Executive Officer, Director (Age 41)
  • David A. Green CPA, Chief Financial Officer, Treasurer, Secretary (Age 55)
  • Jarrett T. Disbrow, Chief Operating Officer
  • Michael Macaluso, Director (Age 66)
  • Gary V. Cantrell, Independent Director
  • Carl C Dockery, Independent Director (Age 53)
  • John Donofrio Jr., Independent Director

How do I buy Aytu Bioscience stock?

Shares of Aytu Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aytu Bioscience's stock price today?

One share of Aytu Bioscience stock can currently be purchased for approximately $2.81.

How big of a company is Aytu Bioscience?

Aytu Bioscience has a market capitalization of $13.76 million and generates $3.22 million in revenue each year. The company earns $-22,500,000.00 in net income (profit) each year or ($27.72) on an earnings per share basis. Aytu Bioscience employs 63 workers across the globe.

How can I contact Aytu Bioscience?

Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]


MarketBeat Community Rating for Aytu Bioscience (AYTU)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  68
MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aytu Bioscience (NASDAQ:AYTU) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.00$3.00$3.00$6.00
Price Target Upside: 421.83% upside421.83% upside421.83% upside943.66% upside

Aytu Bioscience (NASDAQ:AYTU) Consensus Price Target History

Price Target History for Aytu Bioscience (NASDAQ:AYTU)

Aytu Bioscience (NASDAQ:AYTU) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/6/2017HC WainwrightSet Price TargetBuy$3.00N/AView Rating Details
2/17/2017Taglich BrothersReiterated RatingSpeculative BuyN/AView Rating Details
9/26/2016Rodman & RenshawInitiated CoverageBuy$9.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Aytu Bioscience (NASDAQ:AYTU) Earnings History and Estimates Chart

Earnings by Quarter for Aytu Bioscience (NASDAQ:AYTU)

Aytu Bioscience (NASDAQ AYTU) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018N/AView Earnings Details
11/9/2017Q1 2018($7.60)($1.76)$1.08 millionViewN/AView Earnings Details
8/31/2017Q4 2017($12.00)($4.16)ViewN/AView Earnings Details
5/11/2017Q3 2017($0.28)($0.48)$1.08 million$0.89 millionViewN/AView Earnings Details
2/9/201712/31/2016($0.52)($0.55)$1.11 million$0.79 millionViewN/AView Earnings Details
11/7/2016Q1 2017($0.84)($1.17)$1.20 million$0.70 millionViewN/AView Earnings Details
9/1/2016Q4 2016($15.60)($45.40)ViewN/AView Earnings Details
5/11/2016Q3 2016($93.64)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aytu Bioscience (NASDAQ:AYTU) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Aytu Bioscience (NASDAQ:AYTU)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aytu Bioscience (NASDAQ AYTU) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.80%
Insider Trades by Quarter for Aytu Bioscience (NASDAQ:AYTU)

Aytu Bioscience (NASDAQ AYTU) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/20/2016Joshua R DisbrowCEOBuy153,846$0.65$99,999.90153,846View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aytu Bioscience (NASDAQ AYTU) News Headlines

Source:
DateHeadline
Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?
finance.yahoo.com - January 2 at 10:29 AM
Aytu BioScience, Inc. to Present at the 10th Annual LD Micro Main EventAytu BioScience, Inc. to Present at the 10th Annual LD Micro Main Event
finance.yahoo.com - November 29 at 10:48 AM
Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.
finance.yahoo.com - November 28 at 11:15 AM
Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017
finance.yahoo.com - November 28 at 11:15 AM
BRIEF-Aytu Bioscience files for mixed shelf of upto $100 mlnBRIEF-Aytu Bioscience files for mixed shelf of upto $100 mln
www.reuters.com - November 22 at 10:00 PM
AYTU BIOSCIENCE, INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersAYTU BIOSCIENCE, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - November 16 at 8:55 PM
Q1 2017 Aytu BioScience Inc Earnings Release - Time Not SuppliedQ1 2017 Aytu BioScience Inc Earnings Release - Time Not Supplied
biz.yahoo.com - November 7 at 1:40 PM
AYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial StatemenAYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen
biz.yahoo.com - November 2 at 10:18 PM
Aytu BioScience Further Demonstrates Clinical Utility for MiOXSYS™ System as an Aid in the Diagnosis of Male InfertilityAytu BioScience Further Demonstrates Clinical Utility for MiOXSYS™ System as an Aid in the Diagnosis of Male Infertility
www.prnewswire.com - November 1 at 9:11 PM
Aytu BioScience to Present at Two Upcoming Investor ConferencesAytu BioScience to Present at Two Upcoming Investor Conferences
www.prnewswire.com - September 14 at 3:43 PM
Q4 2016 Aytu BioScience Inc Earnings Release - Time Not SuppliedQ4 2016 Aytu BioScience Inc Earnings Release - Time Not Supplied
biz.yahoo.com - September 1 at 12:09 PM
AYTU BIOSCIENCE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhiAYTU BIOSCIENCE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - September 1 at 12:09 PM
Acerus Pharmaceuticals (TRLPF) CEO Tom Rossi on Q2 2016 Results - Earnings Call TranscriptAcerus Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q2 2016 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 4:48 PM
AYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuAYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu
biz.yahoo.com - August 2 at 8:29 AM
Testosterone replacement treatment is opportunity for Colorado companyTestosterone replacement treatment is opportunity for Colorado company
www.bizjournals.com - July 8 at 8:52 PM

SEC Filings

Aytu Bioscience (NASDAQ:AYTU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Aytu Bioscience (NASDAQ AYTU) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.